|
Pharmexcil To Sign MoU With Japanese
Industry Association Soon For Furthering Export Trade
The Pharmaceutical Export Promotion Council of India (Pharmexcil)
is planning to sign a Memorandum of Understanding (MoU) with the Japanese pharma
industry association with an aim to further improve India’s export trade
relations with the Japanese pharma industry.
It is already known that the Japanese markets are one of the
toughest markets to enter into due to their stringent regulatory standards. In
view of this Pharmexcil, is keen in signing an MoU with the Japanese local
industry association to have a constant relationship with the Japanese industry.
Pharmexcil feels that constant interaction with the Japanese local industry
association will help the Indian players to understand their market needs and
also help to synchronise India's regulatory standards with that of the Japanese.
This would help the Indian industry to devise their products in accordance to
the Japanese regulatory norms and help improve Indian exports to Japan.
So far only two big companies from India namely Ranbaxy and
Dr Reddy’s have managed to make their entry into the Japanese markets, that too
in a very limited scale.
Recently, Pharmexcil along with Ministry of commerce and
industries, had participated in “CPhI-Japan” event. During this visit, India’s
major thrust was to promote generics and APIs from India to the Japanese markets
and also to encourage the Japanese companies to participate in India.
“In Asia, Japan holds a great potential for India to tap its
markets. As Japan is the second largest pharmaceutical market in the world,
India needs to pursue its trade relations with Japan to improve its business in
pharmaceuticals, biotechnology and medical devices segments. According to
forecasts it is predicted that by 2014 the Japanese market is expected to grow
to $87 billion. Having known this, our government as well as the industry
leaders should take all the necessary steps to build a long term trade
relationship with Japanese industry,” said Dr P V Appaji, DG, Pharmexil.
As a part of government of India’s efforts to improve mutual
trade between India and Japan, both the countries have signed CEPA agreement.
This agreement will provide an excellent opportunity for Indian pharmaceuticals
manufacturers and exporters to explore opportunities in Japanese market.
“In the coming next 2-3 months we are inviting 2 leading
Japanese journalists as a part of our ‘experience India Programme’. We want the
journalists to go see all the infrastructure installations and industrial units
and have a first hand experience of our quality standards. We want to encourage
not only our players into the Japanese markets but also want Japan to consider
India as a potential sourcing hub,” said Dr Appaji.
“We have also invited officials from Pharmaceuticals and
Medical Devices Agency of Japan (PMDA) - the Japanese FDA, to visit India and
have a first hand experience of our world class manufacturing installations in
the country,” added Appaji.
India is providing all facilities both in terms of
infrastructure and environmental clearances to encourage Japanese investments in
India. They can create their own facilities according to their standards and can
utilize the low cost facilities for developing pharmaceutical products. Not just
the pharmaceutical products, the Japanese companies can also have the
opportunity of exploring the Indian Herbal and health ingredient markets.
Government of India is leaving no stone unturned to improve trade relations with
Japan especially in the pharma and biotechnology sector.
(Ref: The
Chronicle Pharmabiz Dated May 31, 2012)
Lilavati Introduces Bio-prosthetic Heart Valve
Lilavati Hospital, Mumbai has introduced fourth generation
most expensive bio-prosthetic heart valve, “Trifecta Valve” in Mumbai. This new
technology is now available in India which can save your heart and can give you
an increased life span of 20 years and more.
Bhanumati Lakhani, a 69 years old patient who suffered from
aortic heart valve disease, has got latest aortic valve replacement heart
surgery. This surgery was performed by senior heart surgeon, Dr Pavan Kumar
recently at Lilavati Hospital.
Dr Pavan Kumar informed, “It is the most refined fourth
generation bio-prosthesis called “Trifecta Valve” presently available among all
tissue valves. With price tag of Rs. 2,50,000/- per piece, it is expensive but
has latest technology incorporated in designing and manufacturing thus providing
long lasting durability of 20 years and beyond as claimed by manufacturers.” He
further adds, “This fourth generation prosthesis is probably best for heart
patients. The latest trend is towards the use of biological (Tissue Heart Valve)
valve similar to western world now, as patients demand drug free post-operative
period.”
Trifecta Valve was introduced in India in February 2012 after
two years of over 12,000 implantations all over world. It is pericardial tissue
valve placed on Titenum housing with latest Linx Technique anti-calcification
treatment for longer durability, providing best haemodynamic even in smallest
size among all tissue heart valves.
With introduction of this valve, patients of heart valve
disease specially beyond their fifties and ladies in child bearing age,will have
tremendous relief now. This Trifecta Valve eliminates anticoagulation treatment
after implantation. This removes all side effects and consequent complications
of anticoagulation treatment in long term for patients with mechanical heart
valve prosthesis.
Facts suggest that presently among all heart diseases 35% to
40% patients suffer from heart valve disease. This is mainly due to post
Rheumatic infection in childhood or by birth malformations in valves. In elderly
patients this can be degenerative disease of valve. In India, more than 1,50,000
patients undergo heart valve operations of repair and replacement every year.
This is usually considered as safe heart operation with mortality of less than
4% in experienced surgeons and good centres.
Artificial prosthetic heart valves are of two varieties-
mechanical- made of metal with carbon coating and tissue (Biological) - these
are usually imported and cost from 50,000/- per piece upwards.
(Ref: The Chronicle Pharmabiz Dated May 24, 2012)
|
